Data as of Mar 14
| +0.04 / +0.53%|
TG Therapeutics, Inc. is an innovative, clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company develops two therapies targeting hematological malignancies: TG-1101 and TGR-1202. The TG-1101 ublituximab is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. The TGR-1202, is an orally available PI3K delta inhibitor. It also valuates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. TG Therapeutics was founded on May 18, 1993 and is headquartered in New York, NY.
|Michael S. Weiss||Executive Chairman, President & CEO|
|Sean A. Power||Chief Financial Officer, Treasurer & Secretary|
|Robert Niecestro||Executive Vice President-Clinical & Regulatory|
|Hari Miskin||Head-Business Development|
|Jenna A. Bosco||Director-Investor Relations|